Related Experiment Videos
PDGF and FGF stimulate wound healing in the genetically diabetic mouse
D G Greenhalgh1, K H Sprugel, M J Murray
1Department of Surgery, University of Washington, Seattle.
Abstract:
To examine the effects of recombinant growth factors in vivo, impaired wound healing was studied in genetically diabetic C57BL/KsJ-db/db mice. Large full-thickness skin wounds made on the backs of these mice exhibited significant delays in the entry of inflammatory cells into the wound, the formation of granulation tissue, and in wound closure when compared to their nondiabetic littermates. Recombinant human platelet-derived growth factor (rPDGF-BB, 1 or 10 micrograms), recombinant human basic fibroblast growth factor (rbFGF, 1 micrograms), or combinations of both were applied topically to the wounds for 5 to 14 days after wounding. Diabetic mouse wounds treated with rPDGF-BB or rbFGF had many more fibroblasts and capillaries in the wound bed at 10 and 21 days than did wounds treated with the vehicle alone. The animals treated with growth factors also had significantly greater wound closure at 21 days than those treated with the vehicle. Combinations of rPDGF-BB and rbFGF improved all parameters of healing but not to a greater extent than either growth factor alone. The effectiveness of rPDGF-BB and rbFGF suggest that recombinant growth factors may be useful in the treatment of patients with deficient wound repair.
Insights
Recombinant growth factors like platelet-derived growth factor (PDGF-BB) and basic fibroblast growth factor (bFGF) significantly improved impaired wound healing in diabetic mice, suggesting potential therapeutic benefits for patients with healing deficiencies.
Area of Science:
- Regenerative Medicine
- Wound Healing Research
- Diabetic Complications
Background:
- Diabetic patients often experience impaired wound healing, leading to complications.
- Genetically diabetic mice (C57BL/KsJ-db/db) exhibit delayed wound repair.
- Understanding mechanisms to improve diabetic wound healing is crucial.
Purpose of the Study:
- To investigate the efficacy of recombinant growth factors in promoting wound healing in a diabetic mouse model.
- To assess the impact of recombinant human platelet-derived growth factor (rPDGF-BB) and recombinant human basic fibroblast growth factor (rbFGF) on wound repair.
- To evaluate topical application of growth factors for treating impaired wound healing.
Main Methods:
- Induction of full-thickness skin wounds in diabetic (db/db) and non-diabetic mice.
- Topical application of rPDGF-BB (1-10 µg) and rbFGF (1 µg) or vehicle to wounds.
- Assessment of inflammatory cell infiltration, granulation tissue formation, fibroblast and capillary density, and wound closure over 5-21 days.
Main Results:
- Diabetic mouse wounds showed delayed healing compared to non-diabetic controls.
- Treatment with rPDGF-BB or rbFGF increased fibroblast and capillary density in diabetic wounds.
- Growth factor treatment significantly enhanced wound closure in diabetic mice at 21 days.
- Combination therapy showed additive benefits but not superior to single agents.
Conclusions:
- Topical application of rPDGF-BB and rbFGF effectively promotes wound healing in a diabetic mouse model.
- Recombinant growth factors demonstrate potential as therapeutic agents for patients with impaired wound repair.
- Further research into growth factor therapies for diabetic wound complications is warranted.